Literature DB >> 23162772

DNA methylation markers for breast cancer prognosis: Unmasking the immune component.

Sarah Dedeurwaerder1, François Fuks.   

Abstract

Currently, most of the prognostic and predictive gene expression signatures emerging for breast cancer concern the tumor component. In Dedeurwaerder et al. we show that DNA methylation profiling of breast tumors is a particularly sensitive means of capturing features of the immune component of breast tumors. Most importantly, correlation is observed between T-cell marker genes and breast cancer clinical outcome.

Entities:  

Year:  2012        PMID： 23162772      PMCID： PMC3489760          DOI： 10.4161/onci.19996

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Evaluation of the Infinium Methylation 450K technology.

Authors:  Sarah Dedeurwaerder; Matthieu Defrance; Emilie Calonne; Hélène Denis; Christos Sotiriou; François Fuks
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

Review 2.  Gene-expression signatures in breast cancer.

Authors:  Christos Sotiriou; Lajos Pusztai
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

Review 3.  Epigenetic control of T-helper-cell differentiation.

Authors:  Christopher B Wilson; Emily Rowell; Masayuki Sekimata
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

Review 4.  Unravelling the epigenomic dimension of breast cancers.

Authors:  Sarah Dedeurwaerder; Debora Fumagalli; François Fuks
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

5.  Genome-wide DNA methylation profiling using Infinium® assay.

Authors:  Marina Bibikova; Jennie Le; Bret Barnes; Shadi Saedinia-Melnyk; Lixin Zhou; Richard Shen; Kevin L Gunderson
Journal:  Epigenomics       Date:  2009-10       Impact factor: 4.778

Review 6.  Epigenetics in cancer.

Authors:  Shikhar Sharma; Theresa K Kelly; Peter A Jones
Journal:  Carcinogenesis       Date:  2009-09-13       Impact factor: 4.944

7.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

8.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  DNA methylation profiling reveals a predominant immune component in breast cancers.

Authors:  Sarah Dedeurwaerder; Christine Desmedt; Emilie Calonne; Sandeep K Singhal; Benjamin Haibe-Kains; Matthieu Defrance; Stefan Michiels; Michael Volkmar; Rachel Deplus; Judith Luciani; Françoise Lallemand; Denis Larsimont; Jérôme Toussaint; Sandy Haussy; Françoise Rothé; Ghizlane Rouas; Otto Metzger; Samira Majjaj; Kamal Saini; Pascale Putmans; Gérald Hames; Nicolas van Baren; Pierre G Coulie; Martine Piccart; Christos Sotiriou; François Fuks
Journal:  EMBO Mol Med       Date:  2011-11-16       Impact factor: 12.137

Review 10.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.

Authors:  John Stingl; Carlos Caldas
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716
  10 in total
  6 in total

1.  DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.

Authors:  Christine Aaserød Pedersen; Maria Dung Cao; Thomas Fleischer; Morten B Rye; Stian Knappskog; Hans Petter Eikesdal; Per Eystein Lønning; Jörg Tost; Vessela N Kristensen; May-Britt Tessem; Guro F Giskeødegård; Tone F Bathen
Journal:  Breast Cancer Res       Date:  2022-06-24       Impact factor: 8.408

2.  Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer.

Authors:  B Kurklu; R H Whitehead; E K Ong; T Minamoto; J G Fox; J R Mann; L M Judd; A S Giraud; T R Menheniott
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

3.  Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.

Authors:  Xianneng Sheng; Yu Guo; Yang Lu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  Genome-wide methylome and chromatin interactome identify abnormal enhancer to be risk factor of breast cancer.

Authors:  Yuan Wang; Da-Peng Hao; Jing-Jing Li; Li Wang; Li-Jun Di
Journal:  Oncotarget       Date:  2017-07-04

5.  Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.

Authors:  Thilde Terkelsen; Francesco Russo; Pavel Gromov; Vilde Drageset Haakensen; Søren Brunak; Irina Gromova; Anders Krogh; Elena Papaleo
Journal:  Breast Cancer Res       Date:  2020-06-30       Impact factor: 6.466

6.  The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.

Authors:  Carmen Brenner; Judith Luciani; Martin Bizet; Matladi Ndlovu; Eleonore Josseaux; Sarah Dedeurwaerder; Emilie Calonne; Pascale Putmans; Pierre-Francois Cartron; Matthieu Defrance; François Fuks; Rachel Deplus
Journal:  Oncotarget       Date:  2016-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.